Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Tuberous Sclerosis Complex: full-pipeline trial registry

2 of 9 indexed Tuberous Sclerosis Complex trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Tuberous Sclerosis Complex: 9 US clinical trials tracked, 2 recruiting.

Tuberous Sclerosis Complex is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is David M. Ritter, running 1 of these trials.

Enrollment posture brief

Registry condition tuberous-sclerosis-complex

OPEN 2 | RECR 22% | LATE 2 | EARLY 3 | RANK #1916 | SPON 1

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Tuberous Sclerosis Compl (th…22%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Tuberous Sclerosis Complex

Tuberous Sclerosis Complex lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Tuberous Sclerosis Complex on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Tuberous Sclerosis Complex is recruiting below its size-band peers.

    2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Tuberous Sclerosis Complex trials is spread across many organizations.

    David M. Ritter accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Tuberous Sclerosis Complex enrolment sits around 64 participants.

    Median target enrolment is 64 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Tuberous Sclerosis Complex splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31Phase 41

Open and recent trials

9 total, page 1 of 1

RECRUITING 300 participants

Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)

David M. Ritter

NCT06160310

RECRUITING Phase 2 64 participants

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Darcy Krueger

NCT05104983

ACTIVE NOT RECRUITING Phase 3 206 participants

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis Pharmaceuticals

NCT02962414

ACTIVE NOT RECRUITING Phase 4 154 participants

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Jazz Pharmaceuticals

NCT05044819

ACTIVE NOT RECRUITING Phase 1 7 participants

Feasibility of [11C]Acetate-PET in LAM and TSC

Brigham and Women's Hospital

NCT05467397

COMPLETED 450 participants

Tuberous Sclerosis Complex Natural History Study: Renal Manifestations

Children's Hospital Medical Center, Cincinnati

NCT00598455

COMPLETED 40 participants

Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC

University of Alabama at Birmingham

NCT01767779

COMPLETED Phase 2 30 participants

Everolimus for Cancer With TSC1 or TSC2 Mutation

Dana-Farber Cancer Institute

NCT02201212

COMPLETED NA 8 participants

Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex

University of California, Los Angeles

NCT02687633

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Tuberous Sclerosis Complex records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

[11C]acetate Drug
1 trials
everolimus Drug
1 trials
JASPER Behavioral
1 trials
Everolimus Drug
1 trials
Cannabidiol Drug
1 trials
Placebo Drug
1 trials
Sirolimus Drug
1 trials

US sites by state

Facility locations filed on Tuberous Sclerosis Complex trials. A trial with sites in several states counts in each.

Ohio 6 trials
Massachusetts 5 trials
California 5 trials
Texas 3 trials
Pennsylvania 2 trials
New York 2 trials
New Jersey 2 trials
North Carolina 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Tuberous Sclerosis Complex page

9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Tuberous Sclerosis Complex trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • David M. Ritter sponsors the most Tuberous Sclerosis Complex trials on record, review their full trial history before evaluating a specific study. See David M. Ritter's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tuberous Sclerosis Complex condition card totals 9 registered trials; most-linked intervention [11C]acetate; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.